Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TOP2A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TOP2A Mutant Recombinant Protein Panel (Wild-Type & Catalytic Core Variants) High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. Theoretical MW. |
View TOP2A Products |
| Gene Delivery | TOP2A Lentivirus / Promise-ORF Full-length ORF for stable overexpression or reporter cell line construction. |
View TOP2A Products |
| Benchmark Ab | Anti-TOP2A (Research-Grade Diagnostic Clone) Recombinant positive control for IHC/ICC validation. |
View TOP2A Products |
| Validator | TOP2A siRNA Set For knockdown and specificity verification in cell-based assays. |
View TOP2A Products |
| Related Target A | TOP2B Paralog isoform; essential for cardio/neurotoxicity counter-screening and selectivity profiling. |
View TOP2B Products |
| Related Target B | TOP1 Complementary topoisomerase; synergistic DNA damage and combination therapy target. |
View TOP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (Avoid TOP2B-mediated cardiotoxicity) | Purified TOP2A & TOP2B ortholog proteins available with >95% purity; Sequence Verified for off-target liability panels |
| Drug Resistance Profiling (Clinical escape mutations) | TOP2A Mutant Protein Panel (catalytic domain variants); Theoretical MW confirmed; Endotoxin Controlled |
| Lack of Biochemical Controls | High-purity WT TOP2A protein for IC50 calibration; Clinical benchmark compounds supported |
| False Positives in Cellular Assays | Validated siRNA included for target-specificity confirmation (knockdown rescue) |
Live TOP2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TOP2A therapeutics is intensifying, with major players shifting focus from traditional cytotoxic poisons to next-generation catalytic inhibitors and targeted delivery modalities. As first-generation anthracyclines and epipodophyllotoxins remain clinical staples, the next wave of R&D is targeting isoform-selective catalytic inhibition, TOP2A-directed PROTAC degradation, and potent TOP2A inhibitor payloads within antibody-drug conjugates (ADCs). TOP2A gene amplification continues to serve as a critical biomarker in breast and ovarian malignancies, driving companion diagnostic development alongside novel therapeutic regimens. Classic poisons like doxorubicin and etoposide are foundational, but face resistance and toxicity profiles (such as TOP2B-mediated cardiotoxicity), prompting future developments to focus on strict isoform selectivity and novel mechanisms of action to treat refractory solid tumors and hematological malignancies.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Poisons / Catalytic Inhibitors | Established oncology pharma & specialty biotechs | Breast cancer, sarcoma, leukemia, solid tumors | Enzymatic Decatenation & DNA Cleavage Assay (Need high-purity WT and Mutant TOP2A proteins) |
| ADC Payloads (TOP2A Inhibitors) | ADC-focused biopharmaceutical developers | Solid tumors, metastatic breast cancer | Cell-based DNA Damage Reporter Assays (Need Lentivirus for stable reporter lines) |
| PROTAC / Degraders | Emerging targeted protein degradation platforms | Refractory solid tumors | Pull-down & Ternary Complex Validation (Need full-length recombinant TOP2A with native folding) |
Key Mutations and Functional Domains
TOP2A contains key functional domains including the Toprim domain and Topo IIA-type catalytic domain (UniProt P11388). Clinically relevant mutations include: in teniposide (VM-26) resistant cells (dbSNP:rs746765101), in amsacrine resistant cells (dbSNP:rs267607133), and dbSNP:rs28969502. These mutations are critical for drug resistance profiling and assay development.
Related Targets for Combination Therapy
For DDR pathway combination studies and selectivity screening, cross-sell the following targets: TOP2B (for cardiotoxicity counter-screening), TOP1 (complementary topoisomerase), and PARP1 (synergistic DNA damage response pathway).